CEL-SCI   Report issue

For profit Phase 3
Founded: Vienna VA United States (1983)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2010
NCT01265849
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

CEL-SCI Chief Scientific Officer | CEL-SCI Corporation

Active Ingredients

Drugs in Phase 3 Trials (1)

multikine (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Condylomata Acuminata (Phase 1)

Warts (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1